Triumvira Submits Investigational New Drug (IND) Application to the FDA and Clinical Trial Application (CTA) to Health Canada to Evaluate TAC01-CD19, a T Cell Antigen Coupler Therapy, in Ph 1/2 TACTIC-19 Trial

120

AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira submits IND to FDA and CTA to Health Canada to initiate a Phase 1/2, first-in-human trial of its T cell therapy product to fight cancer. http://www.businesswire.com/news/home/20190501005171/en/Triumvira-Submits-Investigational-New-Drug-IND-Application/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

- Advertisement -